PharmNetOnline.com, Online Rx Sources
 
Alprazolam Er 0.5mg Tablet is a CONTROLLED SUBSTANCE and requires a mailed-in doctor signed prescription.

Alprazolam Er 0.5mg Tablet

  Alprazolam Er 0.5mg Tablet 30 Tablets $29.50
  Alprazolam Er 0.5mg Tablet 60 Tablets $54.00
  Alprazolam Er 0.5mg Tablet 90 Tablets $78.50
  Alprazolam Er 0.5mg Tablet 120 Tablets $103.00
  Alprazolam Er 0.5mg Tablet 180 Tablets $152.00
These are self-pay prices and do not take into account any discounts or prescription insurance coverage that you may have. Actual prices are calculated at the time your prescription is processed by the pharmacy.
Controlled Substance Policy: This online pharmacy will only dispense a controlled substance to a person who has a valid prescription issued for a legitimate medical purpose based upon a medical relationship with a prescribing practitioner. This includes at least one prior in-person medical evaluation or medical evaluation via telemedicine in accordance with applicable requirements of section 309 of the Controlled Substances Act.
Rx Prices Online
Find Alphabetically:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z#
Search:
Ordering Prescriptions
Online Resources

Experimental design for optimization of microwave-assisted extraction of benzodiazepines in human plasma.
Authors: Fern#xE1;ndez P, V#xE1;zquez C, Lorenzo RA, Carro AM, Alvarez I, Cabarcos P A simple and fast microwave-assisted-extraction (MAE) method has been evaluated as an alternative to solid-phase extraction (SPE) for the determination of six benzodiazepines widely prescribed in European countries (alprazolam, bromazepam, diazepam, lorazepam, lormetazepam and tetrazepam) in human plasma. For MAE optimization a Doehlert experimental design was used with extraction time, temperature and solvent volume as influential parameters. A desirability function was employed in addition to the simultaneous optimization of the MAE conditions. The analysis of variance showed that the solvent volume had a positive influence on the extraction of all the analytes tested, achieving a statistically sig...

Table of Contents
AbstractIncreasing Off‐Label Use of Antipsychotics for Treating Anxiety DisordersLow‐Dose Antipsychotics Generally Safe in Patients with Intellectual Disability, but Caution Still AdvisedWarfarin and AntidepressantsClinical Guidance for Long‐Term T3 Augmentation in Major DepressionGreater Fracture Risk with Zolpidem Than Alprazolam or Lorazepam in the ElderlySlowing AD Progression with MemantineEPA Supplements for DepressionRisperidone and Decompensation in a Previously Stable PatientNew ApprovalsVarenicline Safety ReviewAdverse Linezolid Interactions with Certain Serotonergic Drugs (Source: The Brown University Psychopharmacology Update)